Cargando…
Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
SIMPLE SUMMARY: This clinical investigation reports the results of a prospective, multicenter phase II trial designed to evaluate the activity and safety of combining non-pegylated liposomal doxorubicin (NPLD) with ifosfamide as a first-line treatment for advanced/metastatic STS. The study results d...
Autores principales: | Buonadonna, Angela, Scalone, Simona, Lombardi, Davide, Fumagalli, Arianna, Guglielmi, Alessandra, Lestuzzi, Chiara, Polesel, Jerry, Canzonieri, Vincenzo, Lamon, Stefano, Giovanis, Petros, Gagno, Sara, Corona, Giuseppe, Mascarin, Maurizio, Belluco, Claudio, De Paoli, Antonino, Fasola, Gianpiero, Puglisi, Fabio, Miolo, Gianmaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605752/ https://www.ncbi.nlm.nih.gov/pubmed/37894403 http://dx.doi.org/10.3390/cancers15205036 |
Ejemplares similares
-
Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023) -
Metabolic Clues to Bile Acid Patterns and Prolonged Survival in Patients with Metastatic Soft-Tissue Sarcoma Treated with Trabectedin
por: Miolo, Gianmaria, et al.
Publicado: (2023) -
Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin
por: Miolo, Gianmaria, et al.
Publicado: (2020) -
Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas
por: Vignoli, Alessia, et al.
Publicado: (2023) -
Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)